MyFinsight
Home
Blog
About
Contact
Download
Download image
Non USOr Europe
$8,388K
Europe
$21,901K
US
$15,913K
Non USOr Europe
$6,772K
Europe
$19,670K
US
$51,763K
Non USOr Europe
$8,106K
Europe
$19,917K
US
$16,549K
Non USOr Europe
$44,568K
Europe
$97,985K
US
$400,292K
OXLUMO
$46,202K
GIVLAARI
$78,204K
ONPATTRO
$44,571K
Amvuttra
$542,844K
Other Collaborations
$13,977K
Regeneron
Pharmaceuticals Incorporation
$30,472K
Roche
$22,759K
Rare
$124,407K
TTR
$587,416K
Royalty
$43,920K
Collaborations
$70,064K
Product
$731,628K
Other income
(expense), net
$135,453K
Total revenues
$1,097,033K
Interest income
$26,630K
Total other expense,
net
$29,419K
Income (loss) from
operations
$131,718K
Loss related to
convertible debt
$1,109K
Interest expense
$129,337K
Total operating costs
and expenses
$965,315K
something is missing
-$2,218K
(provision for) benefit
from income taxes
-$25,282K
Income (loss) before
income taxes
$161,137K
Selling, general and
administrative
$325,374K
Research and development
$372,218K
Cost of goods sold
$267,723K
Net income (loss)
$186,419K
Comprehensive income (loss)
$188,097K
Back
Back
Income Statement
source: myfinsight.com
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
ALNYLAM PHARMACEUTICALS, INC. (ALNY)